AMYT Amryt Pharma Plc

 
TIDMAMYT 
 
 
   Amryt Pharma plc 
 
   Director/PDMR Shareholding 
 
   The following notification is made in accordance with the requirements 
of the EU Market Abuse Regulation (as it forms part of UK law pursuant 
to the European Union (Withdrawal) Act 2018). 
 
   Notification of Transactions by Persons Discharging Managerial 
Responsibilities and Persons Closely Associated with them 
 
   1 
 
   Details of the person discharging managerial responsibilities/person 
closely associated 
 
   a) 
 
   Name 
 
   Ray Stafford 
 
   2 
 
   Reason for the notification 
 
   a) 
 
   Position/status 
 
   Chairman 
 
   b) 
 
   Initial Notification Amendment 
 
   Initial Notification 
 
 
 
   3 
 
   Details of the issuer, emission allowance market participant, auction 
platform, auctioneer or auction monitor 
 
   a) 
 
   Name 
 
   Amryt Pharma plc 
 
   b) 
 
   LEI 
 
   213800YNUJEOJ8L4T95 
 
   4 
 
   Details of the transaction(s): section to be repeated for (i) each type 
of instrument; (ii) each type of transaction; (iii) each date; and (iv) 
each place where transactions have been conducted 
 
   a) 
 
   Description of the financial  instrument, 
 
   type  of 
 
   instrument 
 
   Identification code 
 
   Ordinary shares of GBP0.06 each 
 
   GB00BKLTQ412 
 
   b) 
 
   Nature of the transaction 
 
   Purchase of Shares 
 
   c) 
 
   Price(s) and volume(s) 
 
 
 
 
Price(s)  Volume(s) 
--------  ----------------------- 
GBP2.00   300,100 ordinary shares 
--------  ----------------------- 
 
   d) 
 
   Aggregated information 
 
   -- Aggregated volume 
 
   -- Price 
 
   N/A -- single transaction 
 
   e) 
 
   Date of the transaction 
 
   March 12, 2021 
 
   f) 
 
   Place of the transaction 
 
   London Stock Exchange, AIM 
 
 
 
 
Contacts 
 Joe Wiley, CEO / Rory Nealon, CFO/COO, +353 (1) 518 
 0200, ir@amrytpharma.com https://www.globenewswire.com/Tracker?data=W2OZKRCDVu1NafOZ5xeKbf8WNxEcLDj9Ipt5WG0MX6otgDQ5rpXXPIZQABtB5Ns-il8BS6Y1M9m57L-rwBs4GpsSN5kEAHLDSqJdta6niqE= 
 Edward Mansfield, Shore Capital, NOMAD, +44 (0) 207 
 468 7906, edward.mansfield@shorecap.co.uk 
 Tim McCarthy, LifeSci Advisors, LLC, +1 (212) 915 
 2564, tim@lifesciadvisors.com 
 Amber Fennell, Consilium Strategic Communications, 
 +44 (0) 203 709 5700, fennell@consilium-comms.com 
 https://www.globenewswire.com/Tracker?data=JrGWAGqy2CIwnMK60nxPJtp4gbEVcN_lvn9a-bEFJYJ2hH-7h6gkpts5NtDmUerXUgPFWTmXtvwu7oZoTMZHtmCbWEH5XpvQ7BGpFDKvi9H0VGlIwdQaNg9chOlnP5QO 
 
 
 
 
 
 

(END) Dow Jones Newswires

March 15, 2021 06:00 ET (10:00 GMT)

Amryt Pharma (LSE:AMYT)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025

Amryt Pharma (LSE:AMYT)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025